These findings were confirmed for serum levels of APRIL/TNFSF13 which were increased in patients with tumors containing brisk or non-brisk TIL vs. absent, but were not correlated with disease stage, histological subtypes of melanoma, or circulating levels of LDH. This evidence concerns the gene TNFSF13 and melanoma.